Venlafaksin
 | |
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Effexor, Effexor XR, Elafax |
| Drugs.com | Monografija |
| Način primene | Oralno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 5 h |
| Identifikatori | |
| CAS broj | 93413-69-5  |
| ATC kod | N06AX16 (WHO), N06AX23 |
| PubChem | CID 5656 |
| DrugBank | DB00285 |
| ChemSpider | 5454 |
| KEGG | C07187 |
| ChEBI | CHEBI:9943 |
| ChEMBL | CHEMBL637 |
| Hemijski podaci | |
| Formula | C17H27NO2 |
| Molarna masa | 277,402 |
| |
| |
| Fizički podaci | |
| Tačka topljenja | 215—217 °C (419—423 °F) |
Venlafaksin je organsko jedinjenje, koje sadrži 17 atoma ugljenika i ima molekulsku masu od 277,402 Da.[1][2][3][4][5][6][7]
Osobine[уреди | уреди извор]
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 3 |
| Broj donora vodonika | 1 |
| Broj rotacionih veza | 5 |
| Particioni koeficijent[8] (ALogP) | 3,0 |
| Rastvorljivost[9] (logS, log(mol/L)) | −3,9 |
| Polarna površina[10] (PSA, Å2) | 32,7 |
Reference[уреди | уреди извор]
- ^ Golden RN, Nicholas L: Antidepressant efficacy of venlafaxine. Depress Anxiety. 2000;12 Suppl 1:45-9. PMID 11098413
- ^ Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006 Oct;26(5):482-8. PMID 16974189
- ^ Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 Sep;65(9):1190-6. PMID 15367045
- ^ Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004 Aug;110(3):697-706. PMID 15288411
- ^ Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R: The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005 Feb;45(2):144-52. PMID 15705120
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura[уреди | уреди извор]
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze[уреди | уреди извор]
Mediji vezani za članak Venlafaksin na Vikimedijinoj ostavi
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
